(NASDAQ: INO) Inovio Pharmaceuticals's forecast annual revenue growth rate of 650.46% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.81%.
Inovio Pharmaceuticals's revenue in 2025 is $182,337.On average, 7 Wall Street analysts forecast INO's revenue for 2025 to be $4,531,521, with the lowest INO revenue forecast at $3,412,516, and the highest INO revenue forecast at $5,625,026. On average, 7 Wall Street analysts forecast INO's revenue for 2026 to be $966,111,587, with the lowest INO revenue forecast at $420,001,932, and the highest INO revenue forecast at $2,335,510,743.
In 2027, INO is forecast to generate $4,898,861,820 in revenue, with the lowest revenue forecast at $3,081,764,176 and the highest revenue forecast at $6,883,960,238.